effect
therapi
current
avail
clinic
treatment
flaviviru
infect
recent
advanc
structur
molecular
biolog
flavivirus
provid
new
opportun
develop
antivir
therapi
chapter
summar
current
statu
west
nile
viru
wnv
therapeut
first
strategi
identifi
character
small
molecular
inhibitor
review
strategi
includ
structurebas
ration
design
biochem
enzymebas
screen
revers
genet
systembas
screen
second
known
wnv
inhibitor
summar
small
macromolecular
inhibitor
identifi
inhibit
wnv
macromolecular
inhibitor
includ
wnv
antibodi
interferon
nucleic
acidbas
agent
ie
antisens
oligom
sirna
sinc
antibodybas
therapi
review
elsewher
book
chapter
emphas
nonantibodi
macromolecular
small
molecular
inhibitor
final
new
potenti
antivir
target
issu
relat
wnv
therapeut
discuss
flaviviru
infect
major
public
health
threat
human
vaccin
flaviviru
infect
current
avail
yellow
fever
viru
yfv
japanes
enceph
viru
jev
tickborn
enceph
viru
tbev
west
nile
viru
wnv
vaccin
approv
equin
use
davi
et
al
mink
et
al
ng
et
al
develop
vaccin
dengu
viru
denv
challeng
princip
need
simultan
immun
induc
longlast
protect
four
denv
serotyp
incomplet
immun
individu
may
sensit
dengu
hemorrhag
fever
dengu
shock
syndrom
complic
critic
develop
effect
therapi
treatment
flaviviru
infect
chapter
focus
current
develop
wnv
therapeut
includ
strategi
identif
novel
small
molecular
inhibitor
known
wnv
inhibitor
potenti
new
antivir
target
issu
relat
antivir
develop
sinc
member
flaviviru
genu
share
common
replic
strategi
antivir
studi
flavivirus
wnv
also
select
discuss
step
wnv
life
cycl
potenti
target
antivir
intervent
three
approach
commonli
taken
identifi
inhibitor
includ
structurebas
ration
design
biochem
enzymebas
screen
revers
genet
systembas
screen
approach
advantag
potenti
problem
combin
approach
provid
complementari
inform
individu
inhibitor
singl
open
read
frame
flaviviru
rna
genom
encod
long
polyprotein
coand
posttransl
process
ten
matur
protein
combin
host
proteas
viral
proteas
result
three
structur
protein
capsid
c
membran
envelop
e
seven
nonstructur
protein
lindenbach
et
al
atom
structur
mani
flaviviru
protein
domain
solv
structur
inform
make
ration
design
inhibitor
possibl
among
three
structur
protein
structur
c
solv
nmr
et
al
crystallographi
dokland
et
al
structur
e
ectodomain
avail
preand
postfus
form
bressanelli
et
al
modi
et
al
modi
et
al
rey
et
al
moreov
virion
structur
wnv
denv
determin
use
combin
cryoelectron
microscopi
fit
known
structur
e
electron
densiti
map
kuhn
et
al
mukhopadhyay
et
al
zhang
et
al
among
seven
nonstructur
protein
two
enzymat
activ
ntermin
region
exhibit
proteas
activ
cofactor
respons
cleavag
polyprotein
cytoplasm
side
endoplasm
reticulum
er
ctermin
portion
rna
triphosphatas
ntpase
helicas
activ
rna
triphosphatas
activ
requir
format
cap
structur
viral
genom
ntpase
helicas
activ
need
unwind
rna
structur
viral
replic
ntermin
region
encod
methyltransferas
requir
methyl
cap
guanin
ribos
oh
first
nucleotid
cap
format
ctermin
portion
contain
rnadepend
rna
polymeras
rdrp
crystal
structur
individu
domain
proteas
complex
bowmanbirk
inhibitor
peptid
aleshin
et
al
erbel
et
al
helicas
mancini
et
al
mastrangelo
et
al
wu
et
al
xu
et
al
methyltransferas
egloff
et
al
egloff
et
al
mastrangelo
et
al
zhou
et
al
rdrp
yap
et
al
solv
number
flavivirus
furthermor
crystal
structur
fulllength
recent
resolv
luo
et
al
structur
fulllength
remain
determin
despit
breakthrough
structur
solv
flaviviru
protein
inhibitor
develop
ration
design
virtual
screen
use
methyltransferas
structur
recent
reveal
compound
inhibit
denv
cap
methyl
ic
valu
luzhkov
et
al
studi
use
adenosylmethionin
sam
methyl
donor
start
molecul
search
analog
could
specif
dock
sambind
pocket
methyltransferas
sinc
sam
molecul
bound
pocket
donat
methyl
group
posit
cap
methyl
dong
et
al
identifi
compound
expect
inhibit
methyl
viral
rna
cap
given
flaviviru
methyltransferas
highli
conserv
structur
sequenc
like
compound
would
inhibit
methyltransferas
flavivirus
denv
howev
experi
need
verifi
specul
demonstr
potenc
compound
viral
infect
assay
along
line
sinefungin
sin
sam
analog
transfer
methyl
group
replac
amino
group
inhibit
methyl
wnv
rna
cap
ic
valu
approxim
dong
et
al
bhk
cell
sin
inhibit
wnv
infect
ic
cc
mm
therapeut
index
ti
cc
ic
cytotox
sin
expect
compound
also
bind
host
methyltransferas
suppress
cap
methyl
cellular
mrna
residu
form
sambind
pocket
host
viral
methyltransferas
poorli
conserv
martin
mcmillan
specif
sin
bind
viral
methyltransferas
could
improv
reduc
cytotox
key
enzym
viral
replic
complex
ideal
target
antivir
screen
numer
highthroughput
screen
ht
assay
format
scintil
proxim
assay
spa
radioact
homogen
assay
technolog
commonli
use
screen
larg
compound
librari
spa
method
reli
upon
fact
energi
emit
radioisotop
travel
limit
distanc
aqueou
environ
radioisotopelabel
molecul
bind
microspher
radioisotop
brought
close
proxim
scintil
effect
energi
transfer
b
particl
occur
result
light
emiss
radioisotop
remain
free
solut
distant
scintil
b
particl
dissip
energi
aqueou
medium
remain
undetect
spa
method
use
assess
rdrp
activ
yap
et
al
readili
adapt
flaviviru
helicas
methyltransferas
rdrp
assay
biotinlabel
oligom
anneal
rna
templat
extend
incorpor
hlabel
gtp
presenc
recombin
rdrp
newli
synthes
rna
captur
onto
streptavidincoupl
spa
bead
amount
hgtp
incorpor
indic
rdrp
activ
quantifi
scintil
count
spaformat
methyltransferas
assay
could
similarli
develop
flaviviru
methyltransferas
requir
specif
viral
rna
cap
methyl
dong
et
al
biotinlabel
rna
substrat
contain
termin
sequenc
viral
genom
upon
transfer
hlabel
methyl
group
sam
rna
cap
biotinlabel
rna
captur
onto
streptavidin
spa
bead
measur
scintil
counter
helicas
assay
one
strand
doublestrand
rna
substrat
deriv
anneal
two
rna
complementari
sequenc
end
overhang
label
radioact
nucleotid
rna
strand
coupl
biotin
unwind
doublestrand
rna
biotinyl
rna
could
captur
streptavidin
spa
bead
count
scintil
counter
helicas
activ
reflect
reduct
scintil
signal
proteas
assay
fluorogen
peptid
substratebas
assay
wide
use
mueller
et
al
yusof
et
al
method
use
peptid
substrat
coupl
highli
fluoresc
dye
whose
fluoresc
quench
link
uncleav
peptid
substrat
upon
proteasemedi
cleavag
fluoresc
dye
releas
peptid
therebi
produc
increas
fluoresc
intens
assay
made
possibl
screen
potenti
inhibitor
key
viral
enzym
ht
fashion
major
advantag
enzymebas
assay
identifi
compound
possess
known
target
avail
structur
protein
facilit
improv
inhibitor
howev
compar
cellbas
screen
assay
see
next
section
enzymebas
screen
examin
cellular
uptak
nonspecif
bind
serum
protein
compound
latter
factor
could
dramat
affect
potenc
compound
cell
cultur
anim
genet
cellbas
assay
two
major
advantag
one
target
step
analyz
replic
uptak
compound
cell
requir
repres
authent
therapeut
environ
inhibitor
identifi
cellbas
assay
higher
success
rate
subsequ
anim
experi
sinc
flaviviru
infect
caus
cytopath
effect
cpe
tradit
cellbas
screen
assay
involv
viral
infect
cultur
cell
monitor
inhibit
measur
cpe
jordan
et
al
morrey
et
al
quantif
viral
rna
rtpcr
shi
et
al
unfortun
assay
laborintens
lack
sensit
thu
inform
ideal
screen
larg
compound
librari
overcom
problem
three
cellbas
ht
assay
develop
wnv
drug
discoveri
fig
puigbasago
et
al
antivir
assay
optim
format
valid
known
wnv
inhibitor
proven
use
identifi
new
inhibitor
screen
compound
librari
cell
line
express
wnv
replicon
cell
line
establish
persist
replic
wnv
subgenom
replicon
absenc
structur
gene
lo
et
al
mani
cell
line
harbor
replicon
contain
renilla
luciferas
rluc
substitut
viral
structur
gene
neomycin
phosphotransferas
gene
neo
driven
encephalomyocard
viru
intern
ribosom
lo
et
al
transfect
cell
rlucrep
result
two
distinct
rluc
peak
first
peak
h
posttransfect
repres
input
rna
translat
second
peak
h
posttransfect
repres
viral
rna
synthesi
transient
rlucrep
system
use
dissect
whether
compound
inhibit
viral
translat
rna
synthesi
entri
site
emcv
ire
utr
rlucneorep
fig
incub
rlucneorepcontain
cell
candid
inhibitor
result
decreas
rluc
activ
report
cell
line
allow
screen
inhibitor
step
involv
viral
translat
rna
replic
interrog
step
viral
assembl
entri
one
major
advantag
replicon
cell
line
assay
perform
biosafeti
level
laboratori
infecti
particl
involv
wherea
contain
requir
work
fulllength
wnv
packag
viruslik
particl
vlp
contain
replicon
rna
luciferas
replicon
packag
vlp
suppli
structur
protein
tran
khromykh
et
al
structur
protein
wnv
express
subgenom
promot
semliki
forest
viru
sfv
express
vector
sfvcprme
fig
altern
structur
protein
could
provid
induc
express
cell
line
harvey
et
al
constitut
express
cell
line
harbor
noncytopath
venezuelan
equin
enceph
viru
veev
replicon
fayzulin
et
al
compar
replicon
cell
line
assay
vlpinfect
system
allow
screen
inhibitor
viral
entri
well
translat
rna
synthesi
fulllength
wnv
report
gene
activ
iresrluc
fragment
insert
utr
wnv
genom
rlucwnv
fig
transfect
rlucwnv
rna
bhk
cell
produc
fulllength
report
wnv
dea
et
al
unfortun
report
viru
stabl
multipl
round
infect
cell
cultur
engin
iresrluc
delet
fulllength
viru
nevertheless
earli
passag
report
viru
use
screen
inhibitor
step
viral
life
cycl
puigbasago
et
al
recent
studi
show
stabl
report
yfv
could
gener
heterolog
gene
insert
e
bredenbeek
et
al
foreign
gene
engin
upstream
c
open
read
frame
shustov
et
al
strategi
may
help
gener
wnv
express
report
gene
stabl
fashion
besid
cellbas
assay
transient
rlucreport
replicon
wnv
develop
analyz
mode
action
inhibitor
lo
et
al
replicon
rluc
fuse
infram
footandmouth
diseas
viru
fmdv
proteas
result
engin
replac
viral
structur
gene
result
replicon
rlucrep
fig
transfect
cell
rlucrep
gener
two
distinct
rluc
peak
one
h
posttransfect
anoth
posttransfect
two
rluc
peak
use
differenti
translat
input
rna
translat
replic
rna
respect
similar
approach
use
develop
report
replicon
flavivirus
alvarez
et
al
jone
et
al
puigbasago
et
al
transient
rlucrep
use
examin
whether
compound
inhibit
viral
translat
andor
rna
synthesi
although
number
compound
report
inhibit
wnv
enzym
viral
replic
cell
cultur
shown
vivo
efficaci
base
molecular
weight
antivir
agent
divid
two
categori
macromolecular
inhibitor
small
molecular
inhibitor
antibodybas
therapi
yield
promis
result
treatment
wnv
infect
bennathan
et
al
engl
diamond
juland
et
al
result
agre
previou
studi
show
passiv
administr
monoclon
antibodi
prevent
allevi
enceph
caus
st
loui
enceph
viru
slev
mathew
roehrig
jev
kimurakuroda
yasui
yfv
schlesing
et
al
human
monoclon
antibodi
wnv
e
protein
shown
efficaci
mice
even
administ
singl
dose
day
postinfect
wnv
alreadi
infect
cn
antibodi
show
high
neutral
activ
cell
cultur
provid
equival
protect
mice
hamster
comparison
gammaglobulin
morrey
et
al
morrey
et
al
oliph
et
al
throsbi
et
al
intraven
immunoglobulin
contain
high
titer
antiwnv
antibodi
appear
effect
patient
wn
enceph
openlabel
studi
shimoni
et
al
howev
latter
result
requir
confirm
appropri
control
current
statu
antibodybas
therapi
detail
elsewher
book
interferona
current
clinic
trial
treatment
patient
wnvmediat
meningoenceph
although
interferona
inhibit
wnv
replic
vitro
anderson
rahal
effect
dramat
reduc
viral
replic
initi
probabl
due
blockag
interferon
signal
sever
nonstructur
protein
best
et
al
lin
et
al
liu
et
al
munozjordan
et
al
mice
lack
express
receptor
interferona
b
therefor
defect
interferon
respons
exhibit
higher
mortal
shorter
surviv
time
alter
cellular
tropism
infect
comparison
wildtyp
mice
upon
wnv
inocul
samuel
diamond
treatment
wnvinfect
primari
neuron
interferona
b
howev
appear
independ
increas
surviv
neuron
cultur
signific
recoveri
neurolog
function
five
patient
wnv
cn
diseas
report
treat
interferona
soon
symptom
onset
sayao
et
al
howev
one
interferona
failur
case
report
possibl
due
delay
diagnosi
treatment
complic
chantack
forrest
control
studi
need
demonstr
efficaci
interferon
treatment
antivir
peptid
identifi
murin
brain
cdna
phage
display
librari
screen
bind
wnv
e
protein
bai
et
al
potent
peptid
sequenc
cdviallachlnt
ic
cell
cultur
peptid
abl
penetr
bloodbrain
barrier
mice
mice
challeng
wnv
preincub
peptid
exhibit
reduc
viremia
mortal
compar
mice
challeng
untreat
viru
howev
peptid
elicit
protect
administ
intraperiton
ip
mice
h
postwnv
challeng
short
peptid
repres
fragment
viral
e
protein
also
screen
inhibit
wnv
denv
hrobowski
et
al
underli
rational
peptid
may
interfer
intramolecular
interact
requir
virushost
membran
fusion
effort
result
sever
peptid
repres
junction
region
domain
ii
ic
valu
rang
sinc
flaviviru
membran
fusion
occur
endosom
effici
deliveri
e
peptid
cell
requir
improv
efficaci
two
phosphorodiamid
morpholino
oligom
pmo
report
potent
inhibit
wnv
infect
cell
cultur
dea
et
al
one
pmo
target
first
twenti
nucleotid
wnv
genom
anoth
pmo
target
conserv
sequenc
rna
requir
genom
cycliz
viral
replic
khromykh
et
al
lo
et
al
conjug
argininerich
peptid
pmo
result
effici
cellular
deliveri
greater
potenc
modeofact
analys
show
pmo
target
end
distinctli
suppress
rna
translat
synthesi
respect
sinc
rna
sequenc
conserv
among
mosquitoborn
flavivirus
pmo
inhibit
broad
spectrum
flavivirus
cell
cultur
pmoresist
virus
select
cell
cultur
dea
et
al
virus
resist
end
pmo
accumul
mutat
within
pmotarget
region
wherea
virus
resist
pmo
accumul
mutat
downstream
pmotarget
region
vivo
analysi
show
pmo
could
partial
protect
mice
wnv
diseas
even
administ
day
postinfect
dea
et
al
studi
viral
inocul
pmo
treatment
administ
subcutan
sc
ip
respect
sinc
argininerich
peptid
conjug
pmo
essenti
cellular
uptak
also
respons
toxic
modif
peptid
composit
reduc
toxic
maintain
function
need
improv
pmomedi
therapi
synthet
short
interf
rna
sirna
inhibit
wnv
cell
cultur
mice
potenc
sirna
depend
rout
viral
inocul
sirna
deliveri
one
studi
viral
inocul
sirna
complex
transfect
reagent
cation
lipid
formul
jetsi
fusogen
lipid
dioleoylphosphatidylethanolamin
dope
administ
intracrani
ic
kumar
et
al
mice
receiv
sirna
treatment
h
postvir
inocul
exhibit
surviv
wherea
mocktreat
wnvinfect
mice
show
mortal
anoth
studi
pretreat
mice
sirna
hydrodynam
inject
tail
vein
h
ip
inocul
wnv
yield
partial
protect
bai
et
al
third
cellbas
studi
wnv
replic
greatli
reduc
sirna
introduc
cytoplasmictarget
transfect
prior
establish
viral
replic
howev
sirna
transfect
electropor
suppress
viral
replic
could
achiev
establish
viral
replic
latter
result
indic
transfect
reagent
critic
deliv
sirna
viral
replic
compart
inhibitor
nucleotid
triphosph
synthesi
report
antiwnv
activ
anderson
rahal
jordan
et
al
morrey
et
al
among
ribavirin
mycophenol
acid
mpa
inhibitor
cellular
imp
dehydrogenas
impdh
enzym
essenti
de
novo
biosynthesi
guanin
nucleotid
ribavirin
guanosin
analog
competit
inhibit
impdh
wherea
mpa
nonnucleosid
noncompetit
inhibitor
impdh
ribavirin
mpa
exhibit
broad
spectrum
antivir
activ
primarili
deplet
intracellular
gtp
pool
leyssen
et
al
besid
inhibit
gtp
synthesi
two
antivir
mechan
demonstr
ribavirin
ribavirin
incorpor
viral
rna
basepair
cytidin
uridin
lead
lethal
level
mutagenesi
within
viru
popul
crotti
et
al
day
et
al
ribavirin
block
viral
cap
methyl
bind
gtpbind
pocket
methyltransferas
benarroch
et
al
although
ribavirin
mpa
inhibit
wnv
cell
cultur
treatment
wnvinfect
hamster
ribavirin
led
increas
mortal
morrey
et
al
furthermor
increas
mortal
observ
among
patient
receiv
ribavirin
treatment
wnv
outbreak
chower
et
al
agreement
wnv
result
clinic
benefit
observ
denvinfect
mice
monkey
treat
ribavirin
koff
et
al
malinoski
et
al
similar
ribavirin
increas
mortal
observ
wnvinfect
mice
treat
mpa
noueiri
et
al
collect
result
suggest
ribavirin
mpa
promis
candid
treatment
wnv
infect
vivo
sever
nucleosid
inhibitor
report
antiwnv
activ
cell
cultur
ti
inhibitor
ic
morrey
et
al
addit
shown
broadspectrum
antivir
activ
virus
flavivirida
famili
includ
wnv
hepat
c
replicon
pestiviru
bovin
viral
diarrhea
viru
ojwang
et
al
vivo
efficaci
report
compound
wnv
seri
nucleosid
analog
identifi
inhibit
wnv
imidazo
pyridazin
nucleosid
report
inhibit
wnv
helicas
ic
enzym
viral
titer
reduct
assay
borowski
et
al
antivir
activ
compound
appear
specif
wnv
inhibit
hepat
c
viru
helicas
set
ringexpand
heterocycl
nucleosid
analog
contain
either
imidazo
diazepin
ring
zhang
et
al
ring
system
zhang
et
al
inhibit
wnv
ntpasehelicas
ic
low
micromolar
concentr
random
screen
compound
librari
contain
broad
rang
unrel
small
molecul
reveal
b
ribofuranosyl
benzotriazol
inhibit
wnv
helicas
ic
borowski
et
al
howev
potenc
compound
describ
examin
cell
cultur
small
molecular
peptid
inhibitor
report
inhibit
wnv
proteas
base
crystal
structur
denv
proteas
complex
mung
bean
bowmanbirk
inhibitor
five
compound
identifi
could
mimic
interact
substrat
arginin
proteas
therefor
inhibit
denv
proteas
activ
ganesh
et
al
due
structur
conserv
among
flaviviru
proteas
compound
also
inhibit
wnv
proteas
three
show
ic
recent
advanc
structur
solv
flaviviru
proteas
complex
inhibitor
erbel
et
al
inhibitor
aleshin
et
al
comput
approach
could
extend
improv
current
compound
search
new
inhibitor
block
interact
among
substrat
proteas
flaviviru
serin
proteas
belong
trypsin
superfamili
cleavag
site
flaviviru
proteas
conserv
contain
uniqu
dibas
residu
site
lysin
arginin
follow
residu
short
side
chain
posit
commonli
glycin
serin
alanin
peptid
mimick
conserv
cleavag
substrat
explor
possibl
inhibitor
flaviviru
proteas
wnv
tetrapeptid
variant
deriv
benzoylnorleucinelysineargininearginin
bznkrr
sequenc
inhibit
proteas
ic
knox
et
al
similarli
micromolar
concentr
peptid
keto
amid
backbon
inhibit
denv
proteas
leung
et
al
potenc
compound
may
improv
structur
optim
base
recent
crystal
structur
bznkrr
erbel
et
al
besid
peptid
inhibitor
standard
serin
proteas
inhibitor
test
flaviviru
proteas
aprotinin
inhibit
wnv
denv
proteas
nm
ic
nm
ic
respect
leung
et
al
mueller
et
al
mode
action
aprotinin
recent
reveal
structur
tertiari
complex
consist
wnv
aleshin
et
al
aprotinin
bind
substratemimet
fashion
comparison
structur
complex
without
substrat
tertiari
complex
suggest
induc
fit
mechan
flaviviru
proteas
provid
opportun
develop
inhibitor
block
conform
chang
requir
catalyt
activ
proteas
host
glycosyl
machineri
requir
modif
flaviviru
protein
inhibitor
er
glucosidas
n
nonyldeoxynojirimycin
castanospermin
report
inhibit
jev
denv
low
micromolar
concentr
cell
cultur
courageot
et
al
wu
et
al
glucosidas
inhibitor
block
trim
step
nlink
glycosyl
prm
e
lead
delay
format
preme
heterodim
nonproduct
virion
assembl
n
nonyldeoxynojirimycin
compound
could
partial
protect
mice
jev
infect
mgkgday
wu
et
al
similarli
castanospermin
significantli
reduc
mortal
aj
mice
infect
dose
mgkgday
howev
castanospermin
substanti
suppress
wnv
infect
cell
cultur
mice
whitbi
et
al
number
new
class
wnv
inhibitor
identifi
ht
use
luciferasereport
replicon
cell
line
triaryl
pyrazolin
report
inhibit
wnv
without
detect
cytotox
ic
cc
besid
wnv
compound
also
inhibit
flavivirus
denv
yfv
slev
alphaviru
western
equin
enceph
viru
coronaviru
mous
hepat
viru
rhabdoviru
vesicular
stomat
viru
howev
compound
suppress
orthomyxoviru
influenza
viru
retroviru
modeofact
analysi
wnv
show
compound
block
viral
entri
virion
assembl
specif
suppress
viral
rna
synthesi
goodel
et
al
puigbasago
et
al
one
pyrozolopyrimidin
compound
shown
antivir
activ
ic
cc
gu
et
al
sever
compound
within
sulfonamid
famili
recent
report
inhibit
wnv
cell
cultur
submicromolar
rang
ti
besid
wnv
compound
also
inhibit
flavivirus
one
compound
shown
specif
block
translat
yfv
replicon
alphaviru
sindbi
viru
replicon
emcv
irescontain
mrna
noueiri
et
al
experi
need
determin
exact
target
vivo
efficaci
compound
besid
novel
molecul
minocyclin
tetracyclin
deriv
inhibit
bacteri
translat
bind
ribosom
subunit
thu
prevent
aminoacyl
trna
bind
site
ribosom
recent
shown
inhibit
wnv
infect
cell
cultur
ic
cc
compound
also
inhibit
wnvinduc
apoptosi
suppress
virusinduc
activ
cjun
ntermin
kinas
target
cjun
micha
et
al
minocyclin
previous
shown
protect
mice
fatal
sindbi
viru
enceph
although
inhibit
sindbi
replic
cell
cultur
irani
prow
interest
examin
whether
minocyclin
antiwnv
activ
anim
model
signific
progress
made
toward
develop
therapeut
wnv
among
known
inhibitor
antibodybas
treatment
far
shown
promis
result
due
quasispeci
natur
wnv
errorpron
mutat
viral
rdrp
one
potenti
problem
antibodybas
therapi
rapid
develop
resist
virus
therefor
novel
class
inhibitor
develop
parallel
antibodymedi
therapi
establish
ht
assay
made
possibl
screen
larg
compound
librari
inhibitor
one
challeng
develop
effect
therapeut
wnv
infect
candid
inhibitor
must
effect
reach
cn
clear
viru
infect
neuron
patient
sever
wnv
diseas
often
immun
deficit
present
clinic
attent
rel
late
diseas
cours
ultim
combinatori
strategi
inhibit
viral
replic
boost
protect
immun
respons
minim
cn
injuri
may
effect
singl
antivir
agent
improv
understand
basic
virolog
pathogenesi
flaviviru
continu
open
new
avenu
antivir
develop
exampl
crystallograph
studi
show
viral
e
protein
bressanelli
et
al
modi
et
al
modi
et
al
undergo
sequenti
structur
chang
fusionactiv
transit
small
molecular
inhibitor
could
develop
block
structur
transit
essenti
viralhost
membran
fusion
recent
character
flaviviru
methyltransferas
demonstr
guanin
methyl
viral
rna
cap
essenti
wnv
replic
sinc
flaviviru
methyltransferas
specif
methyl
cap
structur
viral
rna
methyltransferas
repres
antivir
target
dong
et
al
find
flaviviru
protein
antagon
host
innat
immun
respons
also
provid
opportun
develop
antivir
therapi
munozjordan
et
al
inhibitor
block
interferon
antagon
viral
protein
may
allow
innat
antivir
respons
effect
suppress
viral
infect
therefor
reduc
viral
burden
final
host
protein
essenti
viral
replic
could
potenti
target
antivir
therapi
instanc
host
src
famili
kinas
cye
found
critic
matur
wnv
particl
hirsch
et
al
inhibitor
csrc
protein
kinas
recent
shown
potent
inhibit
four
serotyp
denv
ic
valu
submicromolar
rang
chu
yang
clinic
set
essenti
develop
specif
rapid
assay
diagnosi
wnv
infect
prior
initi
chemotherapi
upon
human
infect
wnv
mosquito
inocul
viremia
detect
first
week
postinfect
time
symptom
develop
antibodi
produc
princ
et
al
variou
rtpcrbase
assay
develop
sensit
detect
viral
rna
expect
earli
treatment
antivir
agent
yield
better
therapeut
outcom
late
treatment
cours
infect
sinc
viremia
diminish
symptom
develop
antibodi
produc
serolog
key
diagnost
method
wnv
infect
current
serolog
assay
detect
wnvspecif
antibodi
viral
structur
protein
enzym
immunoassay
eia
tardei
et
al
enzymelink
immunoabsorb
assay
igg
elisa
davi
et
al
tardei
et
al
assay
lack
specif
crossreact
structur
protein
among
flavivirus
luminex
assay
use
recombin
wnv
antigen
report
differenti
wnv
infect
infect
flavivirus
denv
slev
also
differenti
natur
wnv
infect
flaviviru
vaccin
remain
determin
whether
flavivirus
could
use
serolog
diagnosi
viraltyp
specif
diagnost
method
need
antiflaviviru
therapi
also
vaccin
develop
